Mar 07, 2023 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 28, 2023 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
Feb 02, 2023 4:05pm EST Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
Jan 18, 2023 8:05am EST National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
Dec 22, 2022 8:05am EST Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Dec 15, 2022 8:05am EST Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
Dec 01, 2022 5:03pm EST Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Nov 10, 2022 4:05pm EST Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology
Nov 03, 2022 4:01pm EDT Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update
